Project Description
Granules India Limited (Granules or the company) is a leading Contract Manufacturing Organization supplying high volume Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to the bulk over-the-counter (OTC) drugs industry in the US, Europe, Latin America, Australia and India. Granules has three wholly-owned manufacturing plants in India and one plant in China through a 50:50 joint venture (JV). The company is undertaking an investment program estimated to cost about $32 million, comprising of:
- setting up a 6 billion per annum multi-product tableting plant;
- setting up a 3,600 TPA paracetamol API plant;
- installing an additional 3,600TPA of paracetamol PFI capacity;
- investment in a JV in China for ibuprofen API with a capacity of 3,800TPA; and
- development and registration of new products.